Andere Sprachen VACCINEXPAR

Aktien

A403XQ

US9186403013

VCNX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 18.04.2024			% 5 Tage	% 1. Jan.
4,8 ^USD	-0,83 %		-29,41 %	-48,43 %

02.04.	Vaccinex, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
04.03.	Vaccinex, Inc. kündigt Veränderungen in der Geschäftsführung mit Wirkung zum 14. März 2024 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vaccinex, Inc. announced that it has received $1.75 million in funding	12.04.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	02.04.
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02.04.
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29.03.
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28.03.
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	27.03.
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27.03.
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27.03.
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	04.03.
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	04.03.
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	21.02.
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21.02.
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	21.02.
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	21.02.
Vaccinex, Inc. Announces Reverse Stock Split	15.02.
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	07.02.
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	07.02.
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	04.12.
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	13.11.
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen VACCINEXPAR

Aktien

A403XQ

US9186403013

VCNX

Andere Sprachen

Filter